Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1986 Oct;54(1):239–244. doi: 10.1128/iai.54.1.239-244.1986

Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.

J E Pennington, G J Small, M E Lostrom, G B Pier
PMCID: PMC260143  PMID: 3093385

Abstract

A human immunoglobulin G preparation, enriched in antibodies to lipopolysaccharide (LPS) Pseudomonas aeruginosa antigens (PA-IGIV) and murine monoclonal antibodies (MAb) to P. aeruginosa Fisher immunotype-1 (IT-1) LPS antigen and outer membrane protein F (porin), were evaluated for therapeutic efficacy in a guinea pig model of P. aeruginosa pneumonia. The concentration of antibodies to IT-1 LPS was 7.6 micrograms/ml in PA-IGIV and 478 micrograms/ml in the IT-1 MAb preparation. No antibody to IT-1 was detected in MAb to porin. For study, animals were infected by intratracheal instillation of IT-1 P. aeruginosa and then treated 2 h later with intravenous infusions of PA-IGIV, IT-1 MAb, or porin MAb. Control groups received intravenous albumin, and routinely died from pneumonia. Both PA-IGIV (500 mg/kg) and IT-1 MAb (greater than or equal to 2.5 mg/kg) treatment resulted in increased survival (P less than 0.01 to 0.001), and also improved intrapulmonary killing of bacteria. Porin MAb failed to protect from fatal pneumonia. IT-1 MAb treatment produced more survivals than did PA-IGIV treatment but only at dosages of MAb resulting in serum antibody concentrations greater than those achieved with PA-IGIV. PA-IGIV and IT-1 MAb demonstrated in vitro and in vivo (posttreatment guinea pig serum) opsonophagocytic activity for the IT-1 challenge strain. However, the polyclonal preparation required complement, whereas the MAb did not. We conclude that passive immunization with polyclonal hyperimmune P. aeruginosa globulin or with MAb to LPS antigens may be useful in the treatment of acute P. aeruginosa pneumonia. The relative efficacies of such preparations may be limited, however, by their type-specific LPS antibody concentrations.

Full text

PDF
239

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bjornson A. B., Michael J. G. Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. II. Opsonic, agglutinative, and protective capacities of immunoglobulin G anti-Pseudomonas antibodies. Infect Immun. 1972 May;5(5):775–782. doi: 10.1128/iai.5.5.775-782.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bryan C. S., Reynolds K. L. Bacteremic nosocomial pneumonia. Analysis of 172 episodes from a single metropolitan area. Am Rev Respir Dis. 1984 May;129(5):668–671. doi: 10.1164/arrd.1984.129.5.668. [DOI] [PubMed] [Google Scholar]
  3. Collins M. S., Roby R. E. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. Am J Med. 1984 Mar 30;76(3A):168–174. doi: 10.1016/0002-9343(84)90337-1. [DOI] [PubMed] [Google Scholar]
  4. Cryz S. J., Jr, Fürer E., Germanier R. Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide. Infect Immun. 1983 Mar;39(3):1072–1079. doi: 10.1128/iai.39.3.1072-1079.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cryz S. J., Jr, Fürer E., Germanier R. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Infect Immun. 1984 Mar;43(3):795–799. doi: 10.1128/iai.43.3.795-799.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. DePinho R. A., Feldman L. B., Scharff M. D. Tailor-made monoclonal antibodies. Ann Intern Med. 1986 Feb;104(2):225–233. doi: 10.7326/0003-4819-104-2-225. [DOI] [PubMed] [Google Scholar]
  7. Dunn M. M., Toews G. B., Hart D., Pierce A. K. The effects of systemic immunization of pulmonary clearance of Pseudomonas aeruginosa. Am Rev Respir Dis. 1985 Mar;131(3):426–431. doi: 10.1164/arrd.1985.131.3.426. [DOI] [PubMed] [Google Scholar]
  8. Dwyer J. M. Thirty years of supplying the missing link. History of gamma globulin therapy for immunodeficient states. Am J Med. 1984 Mar 30;76(3A):46–52. doi: 10.1016/0002-9343(84)90319-x. [DOI] [PubMed] [Google Scholar]
  9. FOX J. E., LOWBURY E. J. Immunity to Pseudomonas pyocyanea in man. J Pathol Bacteriol. 1953 Apr;65(2):519–531. doi: 10.1002/path.1700650224. [DOI] [PubMed] [Google Scholar]
  10. Fisher M. W., Devlin H. B., Gnabasik F. J. New immunotype schema for Pseudomonas aeruginosa based on protective antigens. J Bacteriol. 1969 May;98(2):835–836. doi: 10.1128/jb.98.2.835-836.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. GAINES S., LANDY M. Prevalence of antibody to Pseudomonas in normal human sera. J Bacteriol. 1955 Jun;69(6):628–633. doi: 10.1128/jb.69.6.628-633.1955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hancock R. E., Carey A. M. Outer membrane of Pseudomonas aeruginosa: heat- 2-mercaptoethanol-modifiable proteins. J Bacteriol. 1979 Dec;140(3):902–910. doi: 10.1128/jb.140.3.902-910.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kazanjian P. H., Pennington J. E. Influence of drugs that block calcium channels on the microbicidal function of human neutrophils. J Infect Dis. 1985 Jan;151(1):15–22. doi: 10.1093/infdis/151.1.15. [DOI] [PubMed] [Google Scholar]
  14. Levin J., Tomasulo P. A., Oser R. S. Detection of endotoxin in human blood and demonstration of an inhibitor. J Lab Clin Med. 1970 Jun;75(6):903–911. [PubMed] [Google Scholar]
  15. Palva E. T., Mäkelä P. H. Lipopolysaccharide heterogeneity in Salmonella typhimurium analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Eur J Biochem. 1980;107(1):137–143. doi: 10.1111/j.1432-1033.1980.tb04634.x. [DOI] [PubMed] [Google Scholar]
  16. Pennington J. E., Harris E. A. Influence of immunosuppression on alveolar macrophage chemotactic activities in guinea pigs. Am Rev Respir Dis. 1981 Mar;123(3):299–304. doi: 10.1164/arrd.1981.123.3.299. [DOI] [PubMed] [Google Scholar]
  17. Pennington J. E. Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa. J Infect Dis. 1979 Jul;140(1):73–80. doi: 10.1093/infdis/140.1.73. [DOI] [PubMed] [Google Scholar]
  18. Pennington J. E., Menkes E. Type-specific vs. cross-protective vaccination for gram-negative bacterial pneumonia. J Infect Dis. 1981 Dec;144(6):599–603. doi: 10.1093/infdis/144.6.599. [DOI] [PubMed] [Google Scholar]
  19. Pennington J. E., Miler J. J. Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections. Infect Immun. 1979 Sep;25(3):1029–1034. doi: 10.1128/iai.25.3.1029-1034.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pennington J. E., Pier G. B. Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia. Rev Infect Dis. 1983 Nov-Dec;5 (Suppl 5):S852–S857. doi: 10.1093/clinids/5.supplement_5.s852. [DOI] [PubMed] [Google Scholar]
  21. Pennington J. E., Reynolds H. Y., Carbone P. P. Pseudomonas pneumonia. A retrospective study of 36 cases. Am J Med. 1973 Aug;55(2):155–160. doi: 10.1016/0002-9343(73)90163-0. [DOI] [PubMed] [Google Scholar]
  22. Pier G. B., Markham R. B., Eardley D. Correlation of the biologic responses of C3H/HEJ mice to endotoxin with the chemical and structural properties of the lipopolysaccharides from Pseudomonas aeruginosa and Escherichia coli. J Immunol. 1981 Jul;127(1):184–191. [PubMed] [Google Scholar]
  23. Pier G. B., Matthews W. J., Jr, Eardley D. D. Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. J Infect Dis. 1983 Mar;147(3):494–503. doi: 10.1093/infdis/147.3.494. [DOI] [PubMed] [Google Scholar]
  24. Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia. A review. Am J Med. 1984 Mar 30;76(3A):53–60. doi: 10.1016/0002-9343(84)90320-6. [DOI] [PubMed] [Google Scholar]
  25. Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983 Jun;147(6):1090–1098. doi: 10.1093/infdis/147.6.1090. [DOI] [PubMed] [Google Scholar]
  26. Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies. Ann Intern Med. 1975 Jun;82(6):819–831. doi: 10.7326/0003-4819-82-6-819. [DOI] [PubMed] [Google Scholar]
  27. Sawada S., Suzuki M., Kawamura T., Fujinaga S., Masuho Y., Tomibe K. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins. J Infect Dis. 1984 Oct;150(4):570–576. doi: 10.1093/infdis/150.4.570. [DOI] [PubMed] [Google Scholar]
  28. Stephens R. S., Tam M. R., Kuo C. C., Nowinski R. C. Monoclonal antibodies to Chlamydia trachomatis: antibody specificities and antigen characterization. J Immunol. 1982 Mar;128(3):1083–1089. [PubMed] [Google Scholar]
  29. Stevens R. M., Teres D., Skillman J. J., Feingold D. S. Pneumonia in an intensive care unit. A 30-month experience. Arch Intern Med. 1974 Jul;134(1):106–111. [PubMed] [Google Scholar]
  30. Tam M. R., Buchanan T. M., Sandström E. G., Holmes K. K., Knapp J. S., Siadak A. W., Nowinski R. C. Serological classification of Neisseria gonorrhoeae with monoclonal antibodies. Infect Immun. 1982 Jun;36(3):1042–1053. doi: 10.1128/iai.36.3.1042-1053.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Yoshimura F., Zalman L. S., Nikaido H. Purification and properties of Pseudomonas aeruginosa porin. J Biol Chem. 1983 Feb 25;258(4):2308–2314. [PubMed] [Google Scholar]
  33. Young L. S. Monoclonal antibodies: technology and application to gram-negative infections. Infection. 1985;13 (Suppl 2):S224–S229. doi: 10.1007/BF01644435. [DOI] [PubMed] [Google Scholar]
  34. Young L. S., Wenzel R. P., Sabath L. D., Pollack M., Pennington J. E., Platt R. The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa. Rev Infect Dis. 1984 Sep-Oct;6 (Suppl 3):S769–S774. doi: 10.1093/clinids/6.supplement_3.s769. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES